Skip to main content
Annals of Intensive Care
Fig. 5 | Annals of Intensive Care

Fig. 5

From: Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Fig. 5

Microbiologic eradication/presumed eradication at TOC by SOFA component score (mITT population). Observed microbiologic eradication is represented by the lighter colored bars; presumed eradication is represented by the darker colored bars. Treatment differences were calculated as unstratified Newcombe 95% CIs; positive differences are in favor of ceftolozane/tazobactam; negative differences are in favor of meropenem. Participants with missing culture and clinical responses that were failure, indeterminate, or missing were counted as presumed failures. CI confidence interval, CV-SOFA cardiovascular SOFA component score, R-SOFA respiratory SOFA component score, SOFA Sequential Organ Failure Assessment, TOC test-of-cure

Back to article page